HIGHLIGHTS
- who: THIEME and collaborators from the Hospital La Fe, Valencia, Spain have published the article: Emicizumab-induced photosensitivity, in the Journal: (JOURNAL) of April/11,/2022
SUMMARY
Hemophilia therapy hemostasis hemophilia A/B Emicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. Report, the authors describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression. A 35 year-old-man diagnosed with hemophilia A and inhibitors started prophylaxis with emicizumab. Six days after the first loading dose of 3 mg/kg (195 mg), he was exposed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.